Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study
Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gemino Fiorelli(Ospedale Maggiore), Lorenzo Morini(Aziende Socio Sanitarie Territoriale Ovest Milanese), Marco Massari(Azienda Sanitaria Unità Locale di Reggio Emilia), Anna Ludovica Fracanzani(University of Milan), Silvia Oldani(Ospedale Maggiore), M. Ballarè(Ospedale di Mirano), Roberto Ceriani(Paoli Hospital), Mauro Borzio(Ospedale Papa Giovanni XXIII), Michela Mattioli(Italian Institute of Technology), Oliviero Riggio(Sapienza University of Rome), Anna Orlandi(IRCCS Policlinico San Donato), Angelo Rossini(Centro Universitário Barão de Mauá), Pierluigi Fiore(Policlinico Umberto I), Caterina Trischitta, Bruno Mario Cesana(Ospedale Maggiore), Giovanni Belloni(Policlinico San Matteo Fondazione), Franco Bissoli(Azienda Ospedaliera Ospedale Civile di Legnano)
Cited by 80
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
ESPEN Guidelines on Enteral Nutrition: Liver disease
|Clinical Nutrition|2006|683
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661